Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) Other Operating Expenses: 2024-2025

  • Silence Therapeutics' Other Operating Expenses rose 21.38% to -$19.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$94.4 million, marking a year-over-year change of. This contributed to the annual value of -$113.6 million for FY2024, which is 20.53% down from last year.
  • As of Q2 2025, Silence Therapeutics' Other Operating Expenses stood at -$19.4 million, which was up 31.64% from -$28.4 million recorded in Q1 2025.
  • Silence Therapeutics' 5-year Other Operating Expenses high stood at -$19.4 million for Q2 2025, and its period low was -$28.4 million during Q1 2025.
  • Its 2-year average for Other Operating Expenses is -$23.6 million, with a median of -$23.3 million in 2024.
  • Over the last 5 years, Silence Therapeutics' Other Operating Expenses had its largest YoY gain of 21.38% in 2025, and its largest YoY loss of 29.02% in 2025.
  • Over the past 2 years, Silence Therapeutics' Other Operating Expenses (Quarterly) stood at -$24.7 million in 2024, then grew by 21.38% to -$19.4 million in 2025.
  • Its last three reported values are -$19.4 million in Q2 2025, -$28.4 million for Q1 2025, and -$24.7 million during Q2 2024.